{"id":"NCT02134028","sponsor":"Sanofi","briefTitle":"Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)","officialTitle":"Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-08-05","primaryCompletion":"2019-10-11","completion":"2019-10-11","firstPosted":"2014-05-08","resultsPosted":"2020-11-02","lastUpdate":"2022-03-28"},"enrollment":2282,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Dupilumab","otherNames":["SAR231893","REGN668"]}],"arms":[{"label":"dupilumab treatment","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo evaluate the long-term safety and tolerability of dupilumab in participants with asthma who participated in a previous dupilumab asthma study (DRI12544, PDY14192, EFC13579, EFC13691).\n\nSecondary Objectives:\n\nTo evaluate the long-term efficacy of dupilumab in participants with asthma who participated in a previous dupilumab asthma clinical study.\n\nTo evaluate dupilumab in participants with asthma who participated in a previous dupilumab asthma clinical study, with regards to:\n\n* Systemic exposure\n* Anti-drug antibodies\n* Biomarkers","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"From the first IMP injection in LTS12551 to the last IMP injection plus 14 weeks (up to 108 weeks)","effectByArm":[{"arm":"Participants From DRI12544: Placebo/Dupilumab","deltaMin":88,"sd":null},{"arm":"Participants From DRI12544: Dupilumab/Dupilumab","deltaMin":369,"sd":null},{"arm":"Participants From EFC13579: Placebo/Dupilumab","deltaMin":414,"sd":null},{"arm":"Participants From EFC13579: Dupilumab/Dupilumab","deltaMin":789,"sd":null},{"arm":"Participants From EFC13691: Placebo/Dupilumab","deltaMin":74,"sd":null},{"arm":"Participants From EFC13691: Dupilumab/Dupilumab","deltaMin":70,"sd":null},{"arm":"Participants From PDY14192: Placebo/Dupilumab","deltaMin":18,"sd":null},{"arm":"Participants From PDY14192: Dupilumab/Dupilumab","deltaMin":13,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":365,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","Colombia","Denmark","France","Germany","Hungary","Israel","Italy","Japan","Mexico","Netherlands","Poland","Romania","Russia","South Africa","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["40458676","39155737","38163585","38013139","37780074","37752621","37431558","37073882","36876957","36509407","36356712","36114102","35809937","35636689","35217003","34597534"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":111},"commonTop":["Nasopharyngitis","Bronchitis","Upper Respiratory Tract Infection","Headache","Injection Site Erythema"]}}